The present invention relates to compositions and methods involving diagnostic tests with multiple test antigens. The present invention involves the expanded use of test antigens as cross-reactive control antigens (CCAs). The invention advantageously provides for enhanced test results analysis by simultaneously providing both test antigen and CCA signal results. These results, in turn, allow useful sample comparison and cross-reference between samples to more accurately identify and verify the fidelity of test results obtained for multiple infective agents at once. The present invention may include compositions and methods for detecting infection by Zika virus or another flavivirus, and may distinguish between infections caused by genetically similar agents.

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

A testing system (10) for an infectious disease, such as Covod-19, has a specimen collector (11) with a housing (12) receiving a specimen of bodily fluids discharged from a cough of a test subject through a specimen inlet (15). After specimen collection, the specimen inlet (15) is closed, and the collector (11) is brough to a mating electronic testing device (13). A seal (55) is removed to expose a transparent specimen tray (43) upon which the specimen has fallen and installed into a collector receptacle (14). A microscope (15) is focused on the specimen, Photographs of the specimen are taken through a microscope (15) and then compared to photographs of specimens known to have indications of infection (26). Based on the comparison, a test result and level of confidence is obtained. The collector (11) is then removed from the testing device (13), and discarded.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.

The present disclosure relates to a respiratory syncytial virus (RSV)-specific binding molecule and an application thereof. The present disclosure also provides a preparation method of the above molecule, and an application of the molecule in the preparation of a product that specifically binds to the RSV surface fusion glycoprotein and the preparation of an RSV vaccine, etc.

Provided herein are mobile systems for sample processing. In some aspects, provided herein are mobile systems for sample processing and methods of use thereof for detection of pathogens in biological samples.

Aspects of the present disclosure relate to polypeptides that specifically bind to a SARS-CoV-2 spike protein, and to methods of use for treatment, prevention, and diagnosis of a SARS-CoV-2 infection. Certain aspects are directed to antibodies and fragments thereof, including Fabs, configured to bind to various epitopes within the receptor binding domain (RBD) of a SARS-CoV-2 spike protein. Compositions, kits, and methods for detection of SARS-CoV-2 are also disclosed.

A method using an endogenous retrovirus (ERV) as a biomarker for detecting a degree of aging of an object or a cell, tissue or organ or isolated cell thereof. A method using an ERV as a target for treating, preventing or delaying aging of the subject or a cell, tissue or organ or isolated cell thereof.

Provided are antibodies that specifically recognize SARS-CoV-2 N protein. Also provided are compositions comprising the antibodies and uses thereof.

A sensor is provided for conversion of chemical and/or biochemical information from an analyte in a sample to an electrical signal. The sensor includes a test cantilever having a base and a deformable part, with a receptor layer for selective uptake of the analyte applied at least atop the deformable part, with a first and second test transducer arranged atop the test cantilever, and a reference cantilever having a base and a deformable part, with a reference layer for selective non-uptake of the analyte applied at least atop the deformable part, with a first and second test transducer arranged atop the reference cantilever. The transducers output an electrical signal corresponding to the occurrence and/or the concentration and/or the amount of the analyte in the sample.